Paradigm chief Paul Rennie on IPPS blockbuster potential, 50% phase three milestone
Welcome to the latest HotCopper Capital Compass, where we’ve this week spoken to Paradigm Biopharma (ASX:PAR) founder and managing director Paul Rennie about Paradigm arriving at its @pivotal” phase three trial, which will be examining outcomes of its flagshi...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.